A Clinical Phase 1 Safety And Pharmacokinetic/Pharmacodynamic Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2011
At a glance
- Drugs Dacomitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 09 Jun 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2011 Planned end date changed from 1 Apr 2011 to 1 May 2011 as reported by ClinicalTrials.gov.